CAMBRIDGE, Mass., June 4, 2013 /PRNewswire-USNewswire/ -- Merrimack Pharmaceuticals, Inc. (NASDAQ: MACK) today announced results from a Phase 1 clinical study that indicate the novel antibody MM-121 can be combined with standard doses of certain cytotoxic agents for investigation as treatment for patients with advanced solid tumors. The research was presented at the 2013 American Society of Clinical Oncology Annual Meeting in Chicago, IL, May 31 – June 4, 2013.

The Phase 1 study of 43 patients with advanced solid tumors established that MM-121 can be combined at its recommended single agent dose with gemcitabine, pemetrexed, cabazitaxel or carboplatin.

MM-121 is a fully human monoclonal antibody that targets ErbB3, a cell surface receptor implicated in tumor growth and survival across multiple malignancies. Preclinical research in several model systems has shown that by inhibiting ErbB3 signaling, MM-121 may restore sensitivity, delay resistance and enhance the effect of certain cytotoxic agents as a combination therapy.

"These data serve as the foundation for moving MM-121 into potential Phase 2 studies in combination with these chemotherapy agents in certain tumor types," said Akos Czibere , MD, Ph.D., Senior Medical Director of the MM-121 program at Merrimack. "MM-121 has the potential to complement the impact of several existing standard-of-care therapies and we look forward to further exploring its promise."

Sanofi and Merrimack entered into an exclusive, global license and collaboration agreement for MM-121 in 2009.

Study Methodology & Results

Abstract Number: 2609Abstract Title: A phase I study of MM-121 in combination with multiple anticancer therapies in patients with advanced soli'/>"/>

(Date:7/31/2015)... July 31, 2015 The Physician-Patient Alliance ... on July 28, 2015, "Surviving Your Hospital Stay: ... for Patient Safety." A sentence was ... read: "PPAHS is a member of ... Opioids. For more information on the National Coalition to ...

(Date:7/31/2015)... TAMPA, Fla. , July 31, 2015 /PRNewswire/ ... announced today that it has made a structured ... -based company specializing in milling, micronization and ... investment will help grow Powdersize,s business while simultaneously ... solutions to Xcelience,s portfolio of capabilities. ...

... 2, 2007 - Accelrys, Inc.,(NASDAQ:ACCL), the leading provider ... that its CFO,Rick Russo, will present at the ... York on July 11, 2007 at,10:30 a.m. ET. ... Hotel July 10th-12th. In attendance will be securities,analysts, ...

(Date:8/1/2015)... ... 2015 , ... AlignLife Office Coordinator Heather Pugh earned the position ... patients at this natural health care center in Winamac. , "Oftentimes patients are in ... role is vital to our approach because we want to focus on the patient ...

(Date:8/1/2015)... ... August 01, 2015 , ... ... in “a trending profession” that comprises a growing percentage of U.S. physicians, and ... , That was one part of the message delivered by John W. Becher, ...

(Date:8/1/2015)... ... August 01, 2015 , ... The condition where veins are enlarged and gnarled ... causing pain and discomfort. Those who spend a lot of time on their feet ... Center is doing what it can to create awareness and provide a cure in ...

(Date:8/1/2015)... (PRWEB) , ... August 01, 2015 , ... Tina Wilcoxson, ... Champions.” , Wilcoxson was given that honor by the National Retail Federation, the largest ... industry. Wilcoxson was one of three Maine business owners to be named as such. ...

... after 163 sickened in 17 states, CDC reports , , ... current outbreak of salmonella in tomatoes, consumers will need ... types of tomatoes for a while. , "The best ... trying to find out exactly where the tomatoes they,re ...

... from a record breaking year of food recalls and ... light the science --,and the politics -- behind food ... nuclear industries., Written plainly and passionately, Wenonah Hauter,s ... fact-filled. The book details the rise,of irradiation in the ...

... In First Acquisition Since Investment from IAC/InterActive Corp, ... of Patient Engagement Capabilities, ARLINGTON, Va., June ... announced today the acquisition of consumer health,information company ... size,of HealthCentral,s email newsletter reach and offers advertisers ...

The Triage Profiler Shortness of Breath Panel provides rapid risk assessment and differential diagnosis of patients presenting to the emergency department with shortness of breath and risk assessment...

... an affordable path to Sonesta flexibility. ... and back adjustments. Packaged with basic ... line of Sonesta add-ons, allowing you ... your needs; complete Sonesta flexibility at ...

... The Sonesta 6202 is ... Packaged with our most popular ... equipped for a myriad of ... powerful (yet quiet) motors allow ...

... bilirubin levels with no pain, no waiting ... the traditional heel stick method or blood ... without regard to gender, gestational age or ... the babys forehead, which reduces the risk ...